It’s the simple additions to your service that improve patient satisfaction, start offering medicines delivery to all of them today
Sep 24, 2026 Weight Loss
A brand-new daily prescription weight-management medication, Foundayo (orforglipron), is now available in the UK and may be prescribed through our registered Simply Meds Online pharmacy and shipped to your door following an online consultation.
Following official authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) on 10 August 2026, Foundayo (orforglipron) became commercially available in the UK on 24 August 2026. This offers more options for those looking for an alternative way to lose and manage their weight.
Developed by Eli Lilly, the manufacturer behind Mounjaro, Foundayo is an innovative non-peptide, oral GLP-1 receptor agonist. Unlike earlier oral treatments, Foundayo offers the convenience of a daily tablet without strict morning fasting rules or liquid limits.
Weight management treatments continue to change and develop. Sign up to receive updates about new options and changes to the treatments offered through our weight management service.
Updates relate to our overall weight management service and do not guarantee access to any particular medicine. Prescription treatments are only provided following a clinical assessment and where considered suitable.
Foundayo is a prescription-only daily tablet for eligible adults designed to support weight loss and weight maintenance long-term. Its active substance is orforglipron, which belongs to the GLP-1 (glucagon-like peptide-1) receptor agonist family.
GLP-1 is a natural hormone released by the gut following a meal. Foundayo works by mirroring or copying your own GLP-1, binding to receptors in the brain to increase feelings of fullness, slowing gastric emptying, and reducing overall hunger and food cravings.
As orforglipron is a small, non-peptide molecule, it is naturally absorbed through the stomach wall like standard tablets. It does not require special absorption enhancers or protective coatings, allowing for a far more flexible daily routine.
Explore our full range of weight loss pills, including Foundayo and Wegovy Pill GLP-1 tablets.
In accordance with its UK licensing criteria, Foundayo is prescribed alongside a balanced, nutritious and lower-calorie diet and increased exercise/activity for adults who meet specific Body Mass Index (BMI) thresholds:
Weight-related conditions considered by prescribers include obstructive sleep apnoea, prediabetes, type 2 diabetes, high blood pressure (hypertension), abnormal blood fats and cardiovascular disease.
Please note: Meeting BMI criteria does not guarantee a prescription. A qualified UK clinician must evaluate your complete medical history to ensure the treatment is safe for you.
Foundayo film-coated tablets are produced in six strength options to allow for a steady, controlled escalation pathway:
To give your body time to adapt and to minimise digestive side effects, treatment follows a step-by-step monthly schedule, gradually increasing over time:
Taking Foundayo fits easily into most daily schedules:
Unlike oral semaglutide options, there is no need to fast overnight before your dose, wait 30 minutes before drinking tea or coffee, or restrict water intake.
Foundayo is currently available on private prescription in the UK following a clinical assessment. As higher strengths contain greater concentrations of the active ingredient, prices vary according to tablet strength.
At Simply Meds Online, *selling prices per 30-day pack are structured as follows:
| Tablet Strength | 30-Day Pack Price |
|---|---|
| 0.8mg (Starting Dose) | £87.97 |
| 2.5mg | £107.97 |
| 5.5mg | £127.97 |
| 9mg | £147.97 |
| 14.5mg | £167.97 |
| 17.2mg (Maximum Dose) | £187.97 |
*Correct at the time of writing. Please double-check current prices and availability on the Foundayo pill page.
Foundayo is not intended as a short-term, quick-fix solution. It is licensed as a long-term medical intervention for both weight loss and ongoing weight maintenance.
Obesity is recognised as a chronic health condition. Clinical guidance supports continuing treatment as long as the medication remains effective, well-tolerated, and clinically appropriate for you. Your prescriber will conduct regular clinical reviews to evaluate your weight progress, metabolic health improvements, and overall well-being.
Like all GLP-1 receptor agonists, Foundayo can cause side effects, although not everyone gets them. Side effects are most common during the initial weeks of starting treatment or following a dose increase.
The most frequently reported effects involve the gastrointestinal system:
These symptoms are typically short-term and lessen or stop altogether as your body adapts to orforglipron. Eating smaller meals, eating slowly, avoiding fatty foods, and staying well-hydrated help manage digestive discomfort.
Rare but serious side effects require immediate medical attention:
For detailed safety parameters, refer to the official Foundayo Patient Information Leaflet (PIL).
Foundayo is a daily prescription weight loss tablet containing orforglipron, a non-peptide GLP-1 receptor agonist. It mimics natural fullness signals in the brain, reducing hunger, curbing cravings, and helping you eat smaller portions.
Yes. Following MHRA approval on 10 August 2026, Foundayo launched for private prescription through UK pharmacies on 24 August 2026.
All new patients begin on the 0.8mg tablet once daily for their first 30 days.
Foundayo is taken once daily.
At Simply Meds Online, prices start at £87.97 for the 0.8mg starting pack, scaling up to £187.97 for the maximum 17.2mg maintenance pack.
There is no fixed treatment end date. It is licensed for ongoing weight management and can be continued long-term under regular clinical supervision.
The most common side effects are mild to moderate digestive issues, including nausea, diarrhoea, constipation, indigestion, and stomach pain.
No. While both are daily weight loss tablets, the Wegovy Pill contains semaglutide and requires strict morning fasting rules. Foundayo contains orforglipron and has no food or water restrictions.
No. Foundayo is an oral tablet containing orforglipron (a single GLP-1 agonist). Mounjaro is a weekly injection containing tirzepatide (a dual GIP/GLP-1 agonist). Both are manufactured by Eli Lilly.
Important: The blog post is intended as a guide and does not replace advice from your GP or healthcare provider. If you have any questions about Foundayo, please get in touch with our pharmacist and prescriber here at Simply Meds Online.
When considering medical treatment for weight mana... Read More..
Understanding potential side effects is an essenti... Read More..
A brand-new daily prescription weight-management m... Read More..
Weight-loss injections and tablets, including GLP-... Read More..
Taking care of your sexual health is an essential... Read More..
Managing adult blemishes alongside fine lines can... Read More..
It’s the simple additions to your service that improve patient satisfaction, start offering medicines delivery to all of them today